{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1362825896228527232.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1186/s40425-019-0813-8"}},{"identifier":{"@type":"URI","@value":"http://link.springer.com/content/pdf/10.1186/s40425-019-0813-8.pdf"}},{"identifier":{"@type":"URI","@value":"http://link.springer.com/article/10.1186/s40425-019-0813-8/fulltext.html"}}],"dc:title":[{"@value":"The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1382825896228527365","@type":"Researcher","foaf:name":[{"@value":"Brian I. Rini"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825896228527240","@type":"Researcher","foaf:name":[{"@value":"Dena Battle"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825896228527241","@type":"Researcher","foaf:name":[{"@value":"Robert A. Figlin"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825896228527237","@type":"Researcher","foaf:name":[{"@value":"Daniel J. George"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825896228527364","@type":"Researcher","foaf:name":[{"@value":"Hans Hammers"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825896228527238","@type":"Researcher","foaf:name":[{"@value":"Tom Hutson"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825896228527363","@type":"Researcher","foaf:name":[{"@value":"Eric Jonasch"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825896228527362","@type":"Researcher","foaf:name":[{"@value":"Richard W. Joseph"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825896228527360","@type":"Researcher","foaf:name":[{"@value":"David F. McDermott"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825896228527242","@type":"Researcher","foaf:name":[{"@value":"Robert J. Motzer"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825896228527361","@type":"Researcher","foaf:name":[{"@value":"Sumanta K. Pal"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825896228527232","@type":"Researcher","foaf:name":[{"@value":"Allan J. Pantuck"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825896228527239","@type":"Researcher","foaf:name":[{"@value":"David I. Quinn"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825896228527233","@type":"Researcher","foaf:name":[{"@value":"Virginia Seery"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825896228527234","@type":"Researcher","foaf:name":[{"@value":"Martin H. Voss"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825896228527366","@type":"Researcher","foaf:name":[{"@value":"Christopher G. Wood"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825896228527236","@type":"Researcher","foaf:name":[{"@value":"Laura S. Wood"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825896228527235","@type":"Researcher","foaf:name":[{"@value":"Michael B. Atkins"}]}],"publication":{"publicationIdentifier":[{"@type":"EISSN","@value":"20511426"}],"prism:publicationName":[{"@value":"Journal for ImmunoTherapy of Cancer"}],"dc:publisher":[{"@value":"BMJ"}],"prism:publicationDate":"2019-12","prism:volume":"7","prism:number":"1","prism:startingPage":"354"},"reviewed":"false","dc:rights":["http://creativecommons.org/licenses/by/4.0/"],"url":[{"@id":"http://link.springer.com/content/pdf/10.1186/s40425-019-0813-8.pdf"},{"@id":"http://link.springer.com/article/10.1186/s40425-019-0813-8/fulltext.html"}],"createdAt":"2019-12-20","modifiedAt":"2021-02-13","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1050025098815775360","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Primary resistance to nivolumab plus ipilimumab therapy affects second-line treatment outcomes in patients with metastatic renal cell carcinoma"},{"@value":"Primary resistance to nivolumab plus ipilimumab therapy affects second‐line treatment outcomes in patients with metastatic renal cell carcinoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360009142904786432","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Complete response of hereditary leiomyomatosis and renal cell cancer (HLRCC)-associated renal cell carcinoma to nivolumab and ipilimumab combination immunotherapy by: a case report"}]},{"@id":"https://cir.nii.ac.jp/crid/1360017282217478400","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Efficacy of combination therapy with pembrolizumab and axitinib for metastatic renal collecting duct cell carcinoma: A report on two cases"}]},{"@id":"https://cir.nii.ac.jp/crid/1360025430199251200","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"The lymphocyte-to-monocyte ratio as a significant inflammatory marker associated with survival of patients with metastatic renal cell carcinoma treated using nivolumab plus ipilimumab therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360294643766121088","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Landscape of prognostic signatures and immunogenomics of the AXL/GAS6 axis in renal cell carcinoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360294643766170752","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Profiling the inhibitory receptors LAG-3, TIM-3, and TIGIT in renal cell carcinoma reveals malignancy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360302865546418048","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Assessments of therapeutic effects according to timings for combined therapy with axitinib and immune check point inhibitor in a mouse renal cell carcinoma model"}]},{"@id":"https://cir.nii.ac.jp/crid/1360302866850918912","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Update on Biomarkers in Renal Cell Carcinoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360580232410676608","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Site-specific patterns of early response to nivolumab plus ipilimumab therapy in advanced renal cell carcinoma patients compared with tyrosine-kinase inhibitors"}]},{"@id":"https://cir.nii.ac.jp/crid/1360857593655674240","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"ELOVL2 promotes cancer progression by inhibiting cell apoptosis in renal cell carcinoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360865814738757376","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Overexpression of SerpinB9 in non-seminomatous germ cell tumors"}]},{"@id":"https://cir.nii.ac.jp/crid/1360866731650638848","@type":"Article","resourceType":"preprint","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Assessments of optimal timing for combined therapy with axitinib and immune check point inhibitor in a mouse renal cell carcinoma model"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1186/s40425-019-0813-8"},{"@type":"CROSSREF","@value":"10.1007/s10689-020-00195-0_references_DOI_KwhGWdo4SD1txkEI5VGJsitUV0q"},{"@type":"CROSSREF","@value":"10.1002/iju5.12504_references_DOI_KwhGWdo4SD1txkEI5VGJsitUV0q"},{"@type":"CROSSREF","@value":"10.1007/s10147-024-02538-8_references_DOI_KwhGWdo4SD1txkEI5VGJsitUV0q"},{"@type":"CROSSREF","@value":"10.1038/s41416-021-01559-8_references_DOI_KwhGWdo4SD1txkEI5VGJsitUV0q"},{"@type":"CROSSREF","@value":"10.1038/s41467-021-25865-0_references_DOI_KwhGWdo4SD1txkEI5VGJsitUV0q"},{"@type":"CROSSREF","@value":"10.3892/or.2021.8234_references_DOI_KwhGWdo4SD1txkEI5VGJsitUV0q"},{"@type":"CROSSREF","@value":"10.1038/s41598-023-37857-9_references_DOI_KwhGWdo4SD1txkEI5VGJsitUV0q"},{"@type":"CROSSREF","@value":"10.1200/edbk_430734_references_DOI_KwhGWdo4SD1txkEI5VGJsitUV0q"},{"@type":"CROSSREF","@value":"10.1111/cas.16326_references_DOI_KwhGWdo4SD1txkEI5VGJsitUV0q"},{"@type":"CROSSREF","@value":"10.1016/j.intimp.2022.109443_references_DOI_KwhGWdo4SD1txkEI5VGJsitUV0q"},{"@type":"CROSSREF","@value":"10.1007/s00795-023-00374-9_references_DOI_KwhGWdo4SD1txkEI5VGJsitUV0q"},{"@type":"CROSSREF","@value":"10.21203/rs.3.rs-1938156/v1_references_DOI_KwhGWdo4SD1txkEI5VGJsitUV0q"}]}